{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:03:54Z","timestamp":1789898634649,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jaad.2014.04.044","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T12:54:41Z","timestamp":1402491281000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Etanercept therapy for toxic epidermal necrolysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Andrea","family":"Paradisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.04.044_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib4","first-page":"e1","article-title":"Toxic epidermal necrolysis. Part I","volume":"173","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000335627","article-title":"Stevens-Johnson syndrome and toxic\u00a0epidermal necrolysis","volume":"97","author":"Harr","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaad.2014.04.044_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"97","author":"Mockenhaupt","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaad.2014.04.044_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1440-0960.2011.00862.x","article-title":"The management of toxic epidermal necrolysis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2014.04.044_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.04.044_bib11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2230.2012.04357.x","article-title":"Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus","volume":"37","author":"Worsnop","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/00015550510037062","article-title":"Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab","volume":"85","author":"Al-Shouli","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.04.044_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report\u00a0of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.04.044_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000338202","article-title":"Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin","volume":"224","author":"Gaitanis","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.04.044_bib16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.1K001","article-title":"Etanercept for toxic epidermal necrolysis","volume":"41","author":"Famularo","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2014.04.044_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1365-4632.2008.04020.x","article-title":"Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis\/toxic epidermal necrolysis: definition of a new model based on translational research","volume":"48","author":"Sadighha","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jaad.2014.04.044_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2014.04.044_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2014.04.044_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib24","first-page":"537","article-title":"Analysis of treatments and deceased cases of severe adverse drug reactions\u2014analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"58","author":"Yamane","year":"2009","journal-title":"Arerugi"},{"key":"10.1016\/j.jaad.2014.04.044_bib25","first-page":"142","article-title":"Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy","volume":"7","author":"Mockenhaupt","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.04.044_bib26","first-page":"5","article-title":"Treatment of severe drug reactions: Stevens\u2013Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2014.04.044_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2014.04.044_bib29","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.04.044_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.04.044_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2014.04.044_bib33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2014.04.044_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2014.04.044_bib38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-4632.2006.02833.x","article-title":"Intravenous immunoglobulin in toxic epidermal necrolysis","volume":"45","author":"Pasic","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib39","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2014.04.044_bib40","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaad.2014.04.044_bib41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2014.04.044_bib42","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2014.04.044_bib43","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2014.04.044_bib44","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2014.04.044_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-1747.2000.00816.x","article-title":"Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"114","author":"Lerner","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/BCR.0b013e31817db8c8","article-title":"Blister fluid composition in a pediatric patient with toxic epidermal necrolysis","volume":"29","author":"Gandhi","year":"2008","journal-title":"J Burn Care Res"},{"key":"10.1016\/j.jaad.2014.04.044_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2009-01-199927","article-title":"Soluble lymphotoxin is an important effector molecule in GVHD and GVL","volume":"115","author":"Markey","year":"2010","journal-title":"Blood"},{"issue":"5 pt 1","key":"10.1016\/j.jaad.2014.04.044_bib50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0190-9622(90)70307-4","article-title":"Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases","volume":"23","author":"Villada","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.04.044_bib52","first-page":"1656","article-title":"Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition","volume":"130","author":"French","year":"2000","journal-title":"Schweiz Med Wochenschr"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214014017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214014017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:05Z","timestamp":1759271405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214014017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0190962214014017"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.04.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept therapy for toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}